Xenon Pharmaceuticals. has been granted a patent for compounds that modulate voltage-gated sodium channels, useful in treating seizure disorders like epilepsy. The patent covers various forms of these compounds, including stereoisomers and pharmaceutically acceptable salts. GlobalData’s report on Xenon Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Xenon Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Xenon Pharmaceuticals's grant share as of July 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12054486B2 encompasses a series of claims related to specific compounds characterized by their chemical structures, particularly those represented by formula (I). The claims detail various compounds, including specific stereoisomers, enantiomers, tautomers, and their pharmaceutically acceptable salts or solvates. Notably, the patent identifies a range of compounds that exhibit potential therapeutic applications, particularly in treating conditions modulated by voltage-gated sodium channels. The compounds listed include various derivatives of imidazo[4,5-c]pyridine and benzo[d]imidazole, among others, with specific substitutions that may enhance their pharmacological properties.
Additionally, the patent outlines methods for treating a variety of diseases and conditions, including numerous forms of epilepsy, seizure disorders, and other neurological and psychiatric conditions such as schizophrenia and Alzheimer's disease. The claims specify that a therapeutically effective amount of the compounds can be administered to mammals in need of treatment. The extensive list of conditions highlights the potential versatility of the compounds in addressing a wide range of medical issues, particularly those related to neurological function and disorders.
To know more about GlobalData’s detailed insights on Xenon Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
